Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.

Scheffel RS, Dora JM, Siqueira DR, Burttet LM, Cerski MR, Maia AL.

Eur J Endocrinol. 2013 May 2;168(6):K51-4. doi: 10.1530/EJE-13-0015. Print 2013 Jun.

2.

Vandetanib for the treatment of medullary thyroid cancer.

Chau NG, Haddad RI.

Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Review.

3.

Vandetanib and the management of advanced medullary thyroid cancer.

Campbell MJ, Seib CD, Gosnell J.

Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9. Review.

PMID:
23202050
4.

Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.

Ton GN, Banaszynski ME, Kolesar JM.

Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. Review.

PMID:
23640345
5.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
6.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.

J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. Erratum in: J Clin Oncol. 2013 Aug 20;31(24):3049.

7.

Vandetanib therapy in medullary thyroid cancer.

Grabowski P, Briest F, Baum RP, Zaknun JJ, Kulkarni HR, Zeitz M, Hörsch D.

Drugs Today (Barc). 2012 Nov;48(11):723-33. doi: 10.1358/dot.2012.48.11.1867323. Review.

PMID:
23170308
8.

Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.

Maciel LMZ, Magalhães PKR.

Arch Endocrinol Metab. 2017 Jul-Aug;61(4):398-402. doi: 10.1590/2359-3997000000267. Epub 2017 Jun 26. Review.

9.

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.

Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A.

Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118. Epub 2016 Sep 30. Review.

PMID:
27650489
10.

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.

Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME.

J Clin Endocrinol Metab. 2012 Apr;97(4):1125-33. doi: 10.1210/jc.2011-2677. Epub 2012 Feb 29. Review.

PMID:
22378813
11.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.

J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6.

12.

SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.

Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S.

Endocr Pract. 2017 Feb;23(2):149-156. doi: 10.4158/EP161259.OR. Epub 2016 Nov 7.

PMID:
27819766
13.

Selective use of vandetanib in the treatment of thyroid cancer.

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.

Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review.

14.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

15.

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.

Lancet Oncol. 2012 Sep;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2. Epub 2012 Aug 14.

PMID:
22898678
16.

The safety of vandetanib for the treatment of thyroid cancer.

Tsang VH, Robinson BG, Learoyd DL.

Expert Opin Drug Saf. 2016 Aug;15(8):1107-13. doi: 10.1080/14740338.2016.1201060. Epub 2016 Jul 4. Review.

PMID:
27301016
17.

Vandetanib for the treatment of thyroid cancer: an update.

Karras S, Anagnostis P, Krassas GE.

Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):469-81. doi: 10.1517/17425255.2014.885015. Epub 2014 Feb 6. Review.

PMID:
24502390
18.

[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].

Chougnet CN, Schlumberger M, Leboulleux S, Baudin E.

Bull Cancer. 2014 Sep;101(9):891-5. doi: 10.1684/bdc.2014.2022. Review. French.

PMID:
25296193
19.

Vandetanib: a guide to its use in advanced medullary thyroid cancer.

Keating GM, Lyseng-Williamson KA, Frampton JE.

BioDrugs. 2012 Dec 1;26(6):431-5. doi: 10.2165/11209360-000000000-00000. Review.

PMID:
22938056
20.

[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].

Segura D, Dupuis C, Chabre O, Piolat C, Durand C, Plantaz D.

Arch Pediatr. 2016 Aug;23(8):840-4. doi: 10.1016/j.arcped.2016.05.007. Epub 2016 Jun 23. French.

PMID:
27345554

Supplemental Content

Support Center